Novo Nordisk Faces a Technical Squeeze as Medicare GLP-1 Plan and Analyst Caucus Diverge

The stock has surged more than 16% over the past month, yet the enthusiasm on Wall Street remains conspicuously muted. Of the 24 analysts covering Novo Nordisk, only seven currently recommend buying the shares. Jefferies recently lifted its price target to 285 Danish kroner from 270, but kept a Hold rating, while JPMorgan stands even more firmly on the sidelines with a neutral call and a target of just 250 kroner. That caution is not without justification: the 14-day relative strength index sits at approximately 73, a level that historically signals a short-term overbought condition and often precedes a pullback or consolidation.

The rally that has pushed the stock to €42.98 in euro terms—or about 42.89 per the latest check—has been fueled by a pair of powerful fundamental developments. On July 1, 2026, the US launched the “Medicare GLP-1 Bridge” program, which caps monthly copayments for Wegovy at $50 for eligible seniors. Up to 3.8 million beneficiaries could gain access under the initiative, a potential game-changer for volume growth. Meanwhile, the UK’s NICE agency recommended Wegovy for the prevention of heart attacks and strokes, citing trial data showing a 20% reduction in major adverse cardiovascular events. These catalysts have helped the stock claw back from a 52-week low of €30.25 set in March 2026—a recovery of nearly 42%—but the shares still trade almost 30% below the July 2025 high of €61.20.

Bull Case: Pipeline Depth and the Volume Equation

Optimists argue that the current valuation fails to price in the next wave of obesity products. Phase 2 data for Amycretin showed weight loss of up to 14.5% in diabetes patients, positioning it as a potential successor to semaglutide. Moreover, the stock now sits 11.4% above its 50-day moving average of €38.49, suggesting momentum remains intact as long as the Medicare ramp translates into a measurable uptick in prescriptions. The expansion of Wegovy’s label to cardiovascular prevention should widen the pool of reimbursing payers, stabilising cash flows even as older GLP-1 products face generic competition.

Technical analysts also point to the fact that the shares have reclaimed ground above the 200-day moving average—a line that had acted as resistance during the prolonged downtrend. If the current buyer interest holds, the next resistance to watch is the 200-day moving average itself at €40.82, though the stock already trades above that level.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Bear Case: Competition, Pricing Pressure, and a High RSI

The contrary view focuses on the structural headwinds that a Medicare-driven volume boost may not fully offset. Novo Nordisk is fighting a legal battle against makers of compounded, unapproved copies of its drugs, but that does little to blunt the competitive threat from Eli Lilly and emerging candidates from Viking Therapeutics. Pricing pressure in the US remains an entrenched problem, and the company’s exposure to lower-margin government programs could compress gross margins in the quarters ahead.

The elevated RSI reading—72 to 73 on a 14-day basis—makes a near-term correction likely. Skeptics note that despite the recent hot streak, the stock is still down about 4% year-to-date in local currency terms and roughly 27% lower than 12 months ago. Past pipeline disappointments, including setbacks with CagriSema and in Alzheimer’s research, serve as reminders that late-stage readouts carry binary risk. If the upcoming half-year report fails to show that rising patient numbers are compensating for pricing erosion, the gap to the 52-week high will remain wide.

The August 5 Verdict

All eyes are now on the half-year results due on August 5, 2026, at 7:30am CEST. The management team’s commentary on early Medicare utilisation and any adjustment to full-year guidance will be the proximate catalyst that decides whether the technical rally gains fundamental legs or fizzles into a consolidation. Should the company demonstrate robust script growth without disproportionate margin damage, the path toward the 200-day moving average and beyond stays open. If instead price competition or supply constraints dominate the earnings call, the support levels tested earlier in the year are likely to face another assault.